Form 4: Organogenesis Chief Legal Officer Boosts Stake with Significant Stock Purchases

Lori Freedman, Chief Administrative and Legal Officer of Organogenesis Holdings Inc., has significantly increased her direct beneficial ownership in the company through a series of open market purchases totaling over 250,000 shares.

Summary

• Lori Freedman, the Chief Administrative and Legal Officer of Organogenesis Holdings Inc. (ORGO), acquired a total of 252,264 shares of Class A Common Stock through multiple transactions.
• On June 4, 2025, Ms. Freedman purchased 100,863 shares at a weighted-average price of $2.8228 per share, with prices ranging from $2.74 to $2.875.
• On June 5, 2025, an additional 142,379 shares were acquired at a weighted-average price of $2.9051 per share, with prices ranging from $2.815 to $2.98.
• On June 6, 2025, a further 9,022 shares were purchased at a weighted-average price of $2.987 per share, with prices ranging from $2.945 to $3.00.
• Following these transactions, Ms. Freedman's direct beneficial ownership of Organogenesis Class A Common Stock stands at 846,459 shares.

Sentiment

Score: 8

Explanation: The sentiment is highly positive due to significant insider buying by a key executive, which typically signals strong confidence in the company's future performance and valuation.

Positives

• A key executive, the Chief Administrative and Legal Officer, has significantly increased her personal stake in the company, signaling strong confidence in Organogenesis's future prospects.
• The purchases were made at varying price points, indicating a sustained belief in the company's value proposition over several days.
• The total acquisition of 252,264 shares represents a substantial investment by an insider, which is often viewed positively by the market.

Risks

• The document itself, being a Form 4, does not detail specific company or market risks, but rather reports a transaction. General market risks and company-specific operational risks always exist, but are not disclosed here.

Future Outlook

This Form 4 filing does not contain any explicit forward-looking statements or guidance regarding the company's future performance or strategic direction. It solely reports insider trading activity.

Industry Context

This Form 4 filing, reporting insider stock purchases, does not provide specific industry context. However, insider buying in the biotechnology or medical device sector (where Organogenesis operates) can sometimes signal management's positive outlook on upcoming product developments, regulatory approvals, or market expansion, though this document does not explicitly state such reasons.

Stakeholder Impact

• Shareholders: May view the insider purchases as a strong vote of confidence from management, potentially leading to increased investor interest and positive sentiment towards the stock.
• Employees: While not directly impacted, a positive signal from leadership can indirectly boost morale and confidence in the company's stability and future.

Key Dates

Recommendation

Keywords

Organogenesis Holdings Inc., ORGO, SEC Form 4, Insider Trading, Stock Purchase, Beneficial Ownership, Executive Stock Acquisition, Lori Freedman, Class A Common Stock